CEO Taylor Schreiber was paid $1,532,763 in fiscal year 2025, ↓ down 52.3% from fiscal year 2024, the 25th percentile of its disclosed peer group (SEC filing 0001193125-26-146293 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$1,532,763 ↓ Taylor Schreiber total, FY2025 | 25th CEO pay percentile vs peers | — CEO-to-median pay ratio | 91.96% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
STTK's next annual pay disclosure, estimated February 24, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Taylor Schreiber | $565,600 | $0 | $0 | $656,531 | $296,940 | $0 | $13,692 | $1,532,763 |
| Chief Executive Officer | ||||||||
| Arunthathy Nirmalini (Lini) Pandite | 502,980 | 0 | 0 | 197,746 | 211,252 | 0 | 20,667 | 932,645 |
| Chief Medical Officer | ||||||||
| Andrew Neill | 467,160 | 0 | 0 | 205,226 | 196,207 | 0 | 14,840 | 883,433 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Taylor Schreiber | $1,532,763 | $3,216,407 | $1,034,408 | ↓ −1,683,644 |
| Arunthathy Nirmalini (Lini) Pandite | 932,645 | — | — | — |
| Andrew Neill | 883,433 | 2,052,586 | 911,757 | ↓ −1,169,153 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Shattuck Labs's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper STTK reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name STTK as a peer is temporarily unavailable — recheck shortly.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Andrew Neill | CFO | $883,433 |
| Arunthathy Nirmalini (Lini) Pandite | Chief Medical Officer | $932,645 |
| Taylor Schreiber | CEO | $1,532,763 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Carrie Brownstein | Former director (through FY2025) | $51,510 |
| Clay Siegall | Independent Director | $68,844 |
| Daniel Baker | Independent Director | $72,528 |
| George Golumbeski | Independent Director | $99,677 |
| Helen M. Boudreau | Independent Director | $77,177 |
| Kate Sasser | Former director (through FY2025) | $51,510 |
| Michael Lee | Former director (through FY2025) | $48,844 |
| Mona Ashiya | Independent Director | $68,694 |
| Neil Gibson | Independent Director | $77,677 |
| Tyler Brous | Former director (through FY2025) | $60,510 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Andrew Neill | Option | 214,000 | 1.18 | — |
| Arunthathy Nirmalini (Lini) Pandite | Option | 206,200 | 1.18 | — |
| Arunthathy Nirmalini (Lini) Pandite | RSU | 8,684 | — | 31,697 |
| Andrew Neill | RSU | 8,331 | — | 30,408 |
| Arunthathy Nirmalini (Lini) Pandite | Option | 1,447 | 7.43 | — |
| Andrew Neill | RSU | 42,375 | — | 154,669 |
| Arunthathy Nirmalini (Lini) Pandite | RSU | 34,856 | — | 127,224 |
| Taylor Schreiber | Option | 171,928 | 9.41 | — |
| Arunthathy Nirmalini (Lini) Pandite | RSU | 18,937 | — | 69,120 |
| Andrew Neill | RSU | 17,462 | — | 63,736 |
| Taylor Schreiber | Option | 684,600 | 1.18 | — |
| Arunthathy Nirmalini (Lini) Pandite | Option | 18,892 | 3.57 | — |
| Arunthathy Nirmalini (Lini) Pandite | Option | 48,412 | 10.09 | — |
| Andrew Neill | Option | 1,389 | 7.43 | — |
| Andrew Neill | Option | 18,918 | 3.57 | — |
| Andrew Neill | Option | 58,855 | 10.09 | — |
The objectives of the Compensation Committee’s compensation philosophy are to attract, retain, and motivate superior executive talent through providing incentives that reward the achievement of performance goals correlated to enhancing shareholder value and aligning the executive’s interests with those of shareholders through long-term incentives linked to specific performance.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-28 | 49,849,887 | 4,356,199 | 1,660 | 91.96% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-28 | 91.96%a |
a. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| George GolumbeskiIndependent · Compensation Committee | $77,500 | — | $22,177 | — | — | $99,677 |
| Neil GibsonIndependent · Audit Committee · Nominating and Corporate Governance Committee (Chair) | 55,500 | — | 22,177 | — | — | 77,677 |
| Helen M. BoudreauIndependent · Audit Committee (Chair) | 55,000 | — | 22,177 | — | — | 77,177 |
| Daniel BakerIndependent · Audit Committee · Newly elected | 17,167 | — | 55,361 | — | — | 72,528 |
| Clay SiegallIndependent · Compensation Committee (Chair) | 46,667 | — | 22,177 | — | — | 68,844 |
| Mona AshiyaIndependent · Nominating and Corporate Governance Committee · Newly elected | 13,333 | — | 55,361 | — | — | 68,694 |
| Tyler BrousIndependent · Departed during FY | 38,333 | — | 22,177 | — | — | 60,510 |
| Carrie BrownsteinIndependent · Departed during FY | 29,333 | — | 22,177 | — | — | 51,510 |
| Kate SasserIndependent · Departed during FY | 29,333 | — | 22,177 | — | — | 51,510 |
| Michael LeeIndependent · Departed during FY | 26,667 | — | 22,177 | — | — | 48,844 |
| Taylor SchreiberEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 10,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $388,833 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $388,833 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Shattuck Labs names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Shattuck Labs.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Iteos Therapeutics | 2024 | Michel Detheux | $628,684 | $0 | $4,965,264 | $421,014 | $6,085,657 |
| 2 | ORIC Pharmaceuticals | 2025 | Jacob Chacko | 657,500 | 826,000 | 3,634,560 | 434,000 | 5,567,164 |
| 3 | Precigen | 2025 | Helen Sabzevari | 1,000,000 | 2,215,000 | 1,069,200 | 1,049,997 | 5,354,329 |
| 4 | CytomX Therapeutics | 2025 | Sean McCarthy | 675,290 | 1,150,463 | 2,158,170 | 749,572 | 4,738,495 |
| 5 | IGM Biosciences | 2023 | Fred Schwarzer | 646,797 | 868,050 | 1,336,743 | 355,738 | 3,207,328 |
| 6 | ALX Oncology | 2025 | Jason Lettmann | 724,500 | 0 | 1,447,488 | 298,856 | 2,470,844 |
| 7 | Black Diamond Therapeutics | 2025 | Mark Velleca | 667,400 | 189,000 | 1,006,030 | 348,717 | 2,234,919 |
| 8 | Precision BioSciences | 2025 | Michael Amoroso | 650,875 | 1,025,086 | 0 | 0 | 2,189,467 |
| 9 | PMV Pharmaceuticals | 2025 | David Mack | 628,461 | 0 | 752,320 | 284,410 | 1,665,191 |
| 10 | Mersana Therapeutics | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| 11 | Shattuck Labs | 2025 | Taylor Schreiber | 565,600 | 0 | 656,531 | 296,940 | 1,532,763 |
| 12 | Prelude Therapeutics | 2025 | Krishna Vaddi | 615,441 | 0 | 412,744 | 309,465 | 1,348,000 |
| 13 | Kezar Life Sciences | 2024 | Christopher Kirk | 600,000 | 0 | 0 | 313,500 | 927,300 |
| 14 | Century Therapeutics | 2025 | Gregory Russotti | 559,650 | 71,120 | 51,240 | 226,658 | 912,320 |
| — | HOOKIPA Pharma | — | — | — | — | — | — | not in coverage universe |
| — | Gritstone bio | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Shattuck Labs | not disclosed | Option 100 | not disclosed | Aon |
| ALX Oncology | not disclosed | not disclosed | not disclosed | Compensia |
| Black Diamond Therapeutics | 95% | not disclosed | not disclosed | Aon Human Capital Solutions (Aon plc) |
| Century Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| CytomX Therapeutics | not disclosed | not disclosed | not disclosed | Aon |
| Gritstone bio | not disclosed | not disclosed | not disclosed | not disclosed |
| HOOKIPA Pharma | not disclosed | not disclosed | not disclosed | not disclosed |
| IGM Biosciences | not disclosed | not disclosed | not disclosed | Aon |
| Iteos Therapeutics | not disclosed | not disclosed | not disclosed | Radford |
| Kezar Life Sciences | not disclosed | not disclosed | not disclosed | not disclosed |
| Mersana Therapeutics | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| ORIC Pharmaceuticals | not disclosed | not disclosed | not disclosed | Aon |
| PMV Pharmaceuticals | not disclosed | Option 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Precigen | 140% | not disclosed | not disclosed | Aon |
| Precision BioSciences | 115% | RSU 100 | not disclosed | Aon |
| Prelude Therapeutics | not disclosed | Option 100 | not disclosed | Compensia |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Taylor Schreiber | DEF 14A | 2026-04-08 | 0001193125-26-146293 | Section “Executive Compensation”. As printed: 1,532,763. Filing ↗machine: r2 · c27 · span 274803–274812 |
| 2 | Section 01, Arunthathy Nirmalini (Lini) Pandite | DEF 14A | 2026-04-08 | 0001193125-26-146293 | Section “Executive Compensation”. As printed: 932,645. Filing ↗machine: r4 · c27 · span 279148–279155 |
| 3 | Section 01, Andrew Neill | DEF 14A | 2026-04-08 | 0001193125-26-146293 | Section “Executive Compensation”. As printed: 883,433. Filing ↗machine: r6 · c27 · span 283449–283456 |
| 4 | Section 08, George Golumbeski | DEF 14A | 2026-04-08 | 0001193125-26-146293 | Section “Director Compensation”. As printed: 99,677. Filing ↗machine: span 236943–236949 |
| 5 | Section 08, Neil Gibson | DEF 14A | 2026-04-08 | 0001193125-26-146293 | Section “Director Compensation”. As printed: 77,677. Filing ↗machine: span 236216–236222 |
| 6 | Section 08, Helen M. Boudreau | DEF 14A | 2026-04-08 | 0001193125-26-146293 | Section “Director Compensation”. As printed: 77,177. Filing ↗machine: span 234013–234019 |
| 7 | Section 08, Daniel Baker | DEF 14A | 2026-04-08 | 0001193125-26-146293 | Section “Director Compensation”. As printed: 72,528. Filing ↗machine: span 233303–233309 |
| 8 | Section 08, Clay Siegall | DEF 14A | 2026-04-08 | 0001193125-26-146293 | Section “Director Compensation”. As printed: 68,844. Filing ↗machine: span 239135–239141 |
| 9 | Section 08, Mona Ashiya | DEF 14A | 2026-04-08 | 0001193125-26-146293 | Section “Director Compensation”. As printed: 68,694. Filing ↗machine: span 232561–232567 |
| 10 | Section 08, Tyler Brous | DEF 14A | 2026-04-08 | 0001193125-26-146293 | Section “Director Compensation”. As printed: 60,510. Filing ↗machine: span 234748–234754 |
| 11 | Section 08, Carrie Brownstein | DEF 14A | 2026-04-08 | 0001193125-26-146293 | Section “Director Compensation”. As printed: 51,510. Filing ↗machine: span 235530–235536 |
| 12 | Section 08, Kate Sasser | DEF 14A | 2026-04-08 | 0001193125-26-146293 | Section “Director Compensation”. As printed: 51,510. Filing ↗machine: span 238448–238454 |
| 13 | Section 08, Michael Lee | DEF 14A | 2026-04-08 | 0001193125-26-146293 | Section “Director Compensation”. As printed: 48,844. Filing ↗machine: span 237681–237687 |
| 14 | Section 08, Taylor Schreiber | DEF 14A | 2026-04-08 | 0001193125-26-146293 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 15 | Section 06, 2026 vote | Form 8-K | 2026-06-02 | 0001193125-26-253784 | Item 5.07 · say-on-pay result. As reported: 91.96% (votes for as printed: 49,849,887). Filing ↗ |
| 16 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 17 | Section 09b board cost (computed) | Computed | — | — | Cash 388,833 + equity 0 + all other 0 = 388,833, summed across the director compensation table rows.machine: formula: Σ = 388,833 |
| 18 | Iteos Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-24 | 0000950170-25-057666 | CEO total compensation as printed in Iteos Therapeutics's own proxy. As printed: 6,085,657. Filing ↗machine: r2 · c27 · span 499272–499281 |
| 19 | ORIC Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186911 | CEO total compensation as printed in ORIC Pharmaceuticals's own proxy. As printed: 5,567,164. Filing ↗machine: r2 · c26 · span 435191–435200 |
| 20 | Precigen, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001140361-26-018214 | CEO total compensation as printed in Precigen's own proxy. As printed: 5,354,329. Filing ↗machine: r2 · c24 · span 721439–721448 |
| 21 | CytomX Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001140361-26-018237 | CEO total compensation as printed in CytomX Therapeutics's own proxy. As printed: 4,738,495. Filing ↗machine: r2 · c24 · span 739353–739362 |
| 22 | IGM Biosciences, Section 10b CEO total | DEF 14A | 2024-04-26 | 0000950170-24-049091 | CEO total compensation as printed in IGM Biosciences's own proxy. As printed: 3,207,328. Filing ↗machine: r2 · c21 · span 824822–824831 |
| 23 | ALX Oncology, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001193125-26-163936 | CEO total compensation as printed in ALX Oncology's own proxy. As printed: 2,470,844. Filing ↗machine: r2 · c29 · span 706901–706910 |
| 24 | Black Diamond Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001104659-26-051474 | CEO total compensation as printed in Black Diamond Therapeutics's own proxy. As printed: 2,234,919. Filing ↗machine: r1 · c41 · span 370031–370040 |
| 25 | Precision BioSciences, Section 10b CEO total | DEF 14A | 2026-04-08 | 0001140361-26-013757 | CEO total compensation as printed in Precision BioSciences's own proxy. As printed: 2,189,467. Filing ↗machine: r2 · c19 · span 829996–830005 |
| 26 | PMV Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001140361-26-016038 | CEO total compensation as printed in PMV Pharmaceuticals's own proxy. As printed: 1,665,191. Filing ↗machine: r2 · c27 · span 469868–469877 |
| 27 | Mersana Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-29 | 0001104659-25-040448 | CEO total compensation as printed in Mersana Therapeutics's own proxy. As printed: 1,613,754. Filing ↗machine: r1 · c41 · span 608188–608197 |
| 28 | Shattuck Labs (subject), Section 10b CEO total | DEF 14A | 2026-04-08 | 0001193125-26-146293 | CEO total compensation as printed in Shattuck Labs's own proxy. As printed: 1,532,763. Filing ↗machine: r2 · c27 · span 274803–274812 |
| 29 | Prelude Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191532 | CEO total compensation as printed in Prelude Therapeutics's own proxy. As printed: 1,348,000. Filing ↗machine: span 557496–557505 |
| 30 | Kezar Life Sciences, Section 10b CEO total | DEF 14A | 2025-04-25 | 0001645666-25-000020 | CEO total compensation as printed in Kezar Life Sciences's own proxy. As printed: 927,300. Filing ↗machine: span 286147–286154 |
| 31 | Century Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001104659-26-049489 | CEO total compensation as printed in Century Therapeutics's own proxy. As printed: 912,320. Filing ↗machine: r3 · c26 · span 521444–521451 |
| 32 | Section 10a, Precigen reciprocity | DEF 14A | — | 0001140361-26-018214 | Precigen's most recent proxy was read; its disclosed peer group does not include Shattuck Labs. Filing ↗ |
| 33 | Section 10a, IGM Biosciences reciprocity | DEF 14A | — | 0000950170-24-049091 | IGM Biosciences's most recent proxy was read; its disclosed peer group does not include Shattuck Labs. Filing ↗ |
| 34 | Section 10a, Precision BioSciences reciprocity | DEF 14A | — | 0001140361-26-013757 | Precision BioSciences's most recent proxy was read; its disclosed peer group does not include Shattuck Labs. Filing ↗ |
| 35 | Section 10a, Mersana Therapeutics reciprocity | DEF 14A | — | 0001104659-25-040448 | Mersana Therapeutics's most recent proxy was read; its disclosed peer group does not include Shattuck Labs. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.